Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9

被引:26
|
作者
Jawad, Zaynab A. R. [1 ,2 ,3 ]
Theodorou, Ioannis G. [1 ,2 ]
Jiao, Long R. [3 ]
Xie, Fang [1 ,2 ]
机构
[1] Imperial Coll London, Dept Mat, London SW7 2AZ, England
[2] Imperial Coll London, London Ctr Nanotechnol, London SW7 2AZ, England
[3] Imperial Coll London, Dept Canc & Surg, London SW12 0HS, England
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
基金
英国工程与自然科学研究理事会;
关键词
PROTEIN MICROARRAYS; FLUORESCENCE ENHANCEMENT; NANOSTRUCTURES; PERFORMANCE; ARRAY;
D O I
10.1038/s41598-017-14688-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Plasmonic gold (Au) nanotriangular arrays, functionalized with a near infrared (NIR) fluorophoreconjugated immunoassay to Carbohydrate Antigen 19-9 (CA 19-9), a pancreatic cancer biomarker, produce optically tunable substrates with two orders of magnitude fluorescence enhancement. Through nanoscale morphological control, the sensitivities of the plasmonic nanotriangular arrays are controllable, paving the way of such optical platforms for multiplexing. Here, we report a limit of detection (LOD) of 7.7 x 10(-7) U. mL(-1) for CA 19-9 by using such tunable Au nanotriangular arrays, a great improvement compared to commercially available CA 19-9 immunoassays. The linear dynamic range was from 1 x 10-6 U. mL(-1) to 1 U. mL(-1), i.e. up to six orders of magnitude. Moreover, high specificity was demonstrated, together with successful validation in serum samples. Their superior tunable sensitivity, along with efforts to combine CA 19-9 with other biomarkers for improved accuracy, open up the possibility for multiplexed NIR-fluorescence enhancement microarrays, for early cancer diagnosis and therapeutic monitoring.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer
    Ishii, H
    Okada, S
    Sato, T
    Wakasugi, H
    Saisho, H
    Furuse, J
    Ishikawa, O
    Matsuno, S
    Yokoyama, S
    HEPATO-GASTROENTEROLOGY, 1997, 44 (13) : 279 - 283
  • [22] EVALUATION OF CA 19-9 LEVELS AS A MARKER FOR PANCREATIC-CANCER
    SHAW, NY
    HUTTON, JM
    DALBOW, MH
    SWANSON, PA
    BORDEN, KK
    CLINICAL CHEMISTRY, 1987, 33 (06) : 1034 - 1034
  • [23] Serum determination of CA 19-9 in diagnosing pancreatic cancer: An obituary
    Pezzilli, R.
    Casadei, R.
    Calculli, L.
    Santini, D.
    Morselli-Labate, A. M.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 (01) : 73 - 74
  • [24] Migration Signature Biomarker Panel Improves Gold Standard CA 19-9 Performance for Detection of Early Stage Pancreatic Cancer in the Blood
    Balasenthil, S.
    Huang, Y.
    Liu, S.
    Marsh, T.
    Chen, J.
    Stass, S. A.
    KuKuruga, D.
    Brand, R.
    Chen, N.
    Frazier, M. L.
    Lee, J. J.
    Srivastava, S.
    Sen, S.
    Killary, A. M.
    PANCREAS, 2019, 48 (10) : 1405 - 1406
  • [25] ELEVATED CA 19-9 PREDICTS UNRESECTABLE PANCREATIC-CANCER
    LAMBIASE, L
    VOGEL, SB
    FORSMARK, CE
    GASTROENTEROLOGY, 1993, 104 (04) : A418 - A418
  • [26] Extremely high level of CA 19-9 in a patient with metastatic pancreatic cancer: Second highest level of CA 19-9 in literature
    Kizilarslanoglu, Muhammet Cemal
    Civelek, Ramazan
    Kilic, Mustafa Kemal
    Kerem, Mustafa
    Gunaydin, Yusuf
    Ulger, Sukran
    JOURNAL OF BUON, 2014, 19 (02): : 583 - 584
  • [27] CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
    Wasan, H. S.
    Springett, G. M.
    Chodkiewicz, C.
    Wong, R.
    Maurel, J.
    Barone, C.
    Rosbrook, B.
    Ricart, A. D.
    Kim, S.
    Spano, J-P
    BRITISH JOURNAL OF CANCER, 2009, 101 (07) : 1162 - 1167
  • [28] CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
    H S Wasan
    G M Springett
    C Chodkiewicz
    R Wong
    J Maurel
    C Barone
    B Rosbrook
    A D Ricart
    S Kim
    J-P Spano
    British Journal of Cancer, 2009, 101 : 1162 - 1167
  • [29] Serum CA 19-9 as a good prognostic biomarker in patients with bladder cancer
    Wang, Qing-hai
    Ji, Zhi-gang
    Chen, Zhi-gang
    Li, Han-zhong
    Fan, Hua
    Fan, Xin-rong
    Shi, Bing-bing
    Fang, Yujiang
    INTERNATIONAL JOURNAL OF SURGERY, 2015, 15 : 113 - 116
  • [30] Development of quantitative immunochromatographic assay for rapid and sensitive detection of carbohydrate antigen 19-9 (CA 19-9) in human plasma
    Baryeh, Kwaku
    Takalkar, Sunitha
    Lund, Michelle
    Liu, Guodong
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 146 : 285 - 291